K-Bio ventures persiguen desarrollo global de fármacos — empresas destacadas 2021

RudaCure: Targeting diseases with high unmet needs to improve quality of life

RudaCure CEO Yongho Kim spent 15 years conducting basic biomedical investigación on pain and trastornos sensoriales at universidad while mentoring the next generation of investigadores. Frustrated by the lack of comercializard technologies that could help pacientes, he founded his own empresa biotecnológica and is now developing tratamientos covering the full spectrum of intractable trastornos sensoriales with high unmet needs — from enfermedad de ojo seco to pain. [Related article: Developing tratamientos for 'trastornos sensoriales' related to quality of life, from enfermedad de ojo seco to pain]

Actualmente, the tratamiento de la enfermedad de ojo seco candidato RCI001 is progresoing at the fastest pace, with planea advance to Phase 1 ensayo clínicos nacionalally and internacionally el próximo año. Además, the tratamiento del dolor RCI002, atopic dermatitis tratamiento RCI003, metastatic cancer tratamiento RCI004, and AMD/age-related macular degeneration tratamiento RCI005 are also under desarrollo.

메디게이트뉴스